These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10686275)

  • 41. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Normative Fecal Calprotectin Concentrations in Guatemalan Preschoolers Are High Relative to Children Reported Elsewhere.
    Soto-Méndez MJ; Romero-Abal ME; Schümann K; Gil Á; Solomons NW
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):238-244. PubMed ID: 27101538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid.
    Berstad A; Arslan G; Folvik G
    Scand J Gastroenterol; 2000 Jan; 35(1):64-9. PubMed ID: 10672837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
    Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
    Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.
    Lehmann FS; Trapani F; Fueglistaler I; Terracciano LM; von Flüe M; Cathomas G; Zettl A; Benkert P; Oertli D; Beglinger C
    World J Gastroenterol; 2014 May; 20(17):4994-9. PubMed ID: 24803811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High prevalence of NSAID enteropathy as shown by a simple faecal test.
    Tibble JA; Sigthorsson G; Foster R; Scott D; Fagerhol MK; Roseth A; Bjarnason I
    Gut; 1999 Sep; 45(3):362-6. PubMed ID: 10446103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salivary calprotectin levels are raised in patients with oral candidiasis or Sjögren's syndrome but decreased by HIV infection.
    Sweet SP; Denbury AN; Challacombe SJ
    Oral Microbiol Immunol; 2001 Apr; 16(2):119-23. PubMed ID: 11240866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.
    Lasson A; Stotzer PO; Öhman L; Isaksson S; Sapnara M; Strid H
    J Crohns Colitis; 2015 Jan; 9(1):26-32. PubMed ID: 25008478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children.
    Chen CC; Huang JL; Chang CJ; Kong MS
    J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):541-7. PubMed ID: 22699836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.